SY-5609

News alerts, weekly reports and conference planners

Company:

Syros

Drug class:

CDK7 inhibitor

Related drugs:

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	SY-5609 Sensitive: C2 – Inclusion Criteria SY-5609 Sensitive : C2	SY-5609 Sensitive: C2 – Inclusion Criteria SY-5609 Sensitive : C2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D

Associations
(3)